Soligenix, Inc.
SNGX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.37
KIRA · Stoqly’s AI analyst, in plain words
- Soligenix, Inc. lost $11.1M in fiscal 2025.
- Free cash flow was −$10.3M in fiscal 2025, — of revenue.
Market cap
$5.8M
P/E
—
Revenue
—
Net income
−$11.1M
Free cash flow
−$10.3M
Operating margin
—
Soligenix, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$11.1M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Soligenix, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- SOLIGENIX, INC.
- CIK
- 0000812796
Soligenix, Inc. · SNGX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.8M | $0.9M | $0.8M | $0.1M | — |
| Revenue growth | −65.1% | 15.1% | −11.5% | −85.8% | — |
| Net interest income | −$0.9M | — | — | — | — |
| Gross margin | 11.6% | 42.0% | 11.6% | 0.0% | — |
| Operating margin | −1,589.1% | −1,500.6% | −917.1% | −7,905.8% | — |
| Net income | −$12.6M | −$13.8M | −$6.1M | −$8.3M | −$11.1M |
| Net margin | −1,522.6% | −1,454.1% | −731.6% | −6,923.5% | — |
| Diluted EPS | −$4.69 | −$4.81 | −$12.66 | −$4.98 | −$2.14 |
| Cash | |||||
| Cash from operations | −$11.7M | −$12.6M | −$8.6M | −$8.4M | −$10.3M |
| Capital expenditure | — | — | — | — | $0.0M |
| Free cash flow | — | — | — | — | −$10.3M |
| Share count change | −90.3% | 7.3% | −83.1% | 242.4% | 212.5% |
| Debt and strength | |||||
| Cash and short-term investments | $26.0M | $13.4M | $8.4M | $7.8M | $7.9M |
| Debt incl. finance leases | — | $0.0M | $1.0M | $0.0M | — |
| Deposits | $0.3M | — | — | — | — |
| Shareholders' equity | $10.7M | −$2.5M | $2.5M | $4.1M | $5.3M |
| Current ratio | 4.2x | 0.8x | 1.5x | 1.8x | 2.4x |
| Returns and quality | |||||
| Return on equity | −173.5% | −334.4% | −23,801.2% | −249.0% | −235.5% |
| Return on tangible equity | −117.1% | — | −243.4% | −200.7% | −209.4% |
| Piotroski F-score | 4 | 3 | 4 | 2 | — |
| Altman Z'' | −22.6 | −58.2 | −77.8 | −88.3 | −90.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Soligenix, Inc. · SNGX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.37 a share, the company is worth $5.8M.
Source: SEC EDGAR XBRL filings (CIK 0000812796). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.